Profile data is unavailable for this security.
About the company
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
- Revenue in HKD (TTM)0.00
- Net income in HKD-1.14bn
- Incorporated2018
- Employees225.00
- LocationKintor Pharmaceutical LtdNo. 20 Songbei RoadSuzhou Industrial ParkSUZHOU 215123ChinaCHN
- Phone+86 51 262639909
- Websitehttps://www.kintor.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clover Biopharmaceuticals Ltd | 42.17m | -148.84m | 382.63m | 387.00 | -- | -- | -- | 9.07 | -0.1192 | -0.1192 | 0.0338 | -0.6074 | 0.0116 | 0.0098 | 0.7449 | 108,977.30 | -4.08 | -- | -16.40 | -- | 61.75 | -- | -352.92 | -- | 0.5281 | -1.45 | -- | -- | -- | -- | 94.35 | -- | -- | -- |
Sirnaomics Ltd | 0.00 | -614.58m | 415.41m | 145.00 | -- | 1.32 | -- | -- | -8.08 | -8.08 | 0.00 | 3.58 | 0.00 | -- | -- | 0.00 | -70.91 | -- | -71.22 | -- | -- | -- | -- | -- | -- | -- | 0.6176 | -- | -- | -- | 10.88 | -- | -- | -- |
Antengene Corporation Ltd | 72.31m | -624.40m | 438.68m | 201.00 | -- | 0.3559 | -- | 6.07 | -1.01 | -1.01 | 0.1176 | 1.83 | 0.0358 | 0.9773 | 3.41 | 359,752.10 | -30.91 | -53.57 | -36.46 | -58.94 | 81.74 | -- | -863.51 | -1,987.01 | 6.43 | -- | 0.1491 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
Kintor Pharmaceutical Ltd | 0.00 | -1.14bn | 460.92m | 225.00 | -- | 0.9365 | -- | -- | -2.65 | -2.65 | 0.00 | 1.10 | 0.00 | 0.1448 | -- | 0.00 | -72.55 | -50.15 | -89.09 | -58.43 | -- | -27.62 | -- | -10,511.41 | 2.10 | -- | 0.3566 | -- | -- | -- | -11.15 | -- | -32.49 | -- |
HighTide Therapeutics Inc | 0.00 | -1.01bn | 571.40m | 66.00 | -- | 0.6951 | -- | -- | -2.13 | -2.13 | 0.00 | 1.60 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0229 | -- | -- | -- | -393.76 | -- | -- | -- |
Genor Biopharma Holdings Ltd | 0.00 | -724.51m | 632.44m | 104.00 | -- | 0.4851 | -- | -- | -1.43 | -1.43 | 0.00 | 2.54 | 0.00 | 0.00 | -- | 0.00 | -37.91 | -55.46 | -44.02 | -63.73 | -- | 66.56 | -- | -14,819.18 | 5.38 | -- | 0.006 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
JW (Cayman) Therapeutics Co Ltd | 186.78m | -825.11m | 747.12m | 398.00 | -- | 0.4103 | -- | 4.00 | -2.00 | -2.00 | 0.4539 | 4.39 | 0.0704 | 1.68 | 65.54 | 469,308.80 | -31.11 | -39.77 | -35.21 | -44.00 | 50.74 | -- | -441.74 | -1,316.81 | 3.86 | -47.82 | 0.1592 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
Brii Biosciences Ltd | 662.88k | -187.83m | 766.49m | 128.00 | -- | 0.2286 | -- | 1,156.30 | -0.2582 | -0.2582 | 0.0009 | 4.59 | 0.0002 | -- | -- | 5,178.78 | -5.60 | -- | -5.84 | -- | -- | -- | -29,881.69 | -- | -- | -- | 0.001 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
Sunho Biologics Inc | -100.00bn | -100.00bn | 968.20m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -155.25 | -- | -- | -- |
Jacobio Pharmaceuticals Group Co Ltd | 68.24m | -385.83m | 1.34bn | 301.00 | -- | 1.17 | -- | 19.67 | -0.4991 | -0.4991 | 0.0883 | 1.46 | 0.0419 | -- | 5.21 | 226,723.30 | -23.66 | -45.76 | -26.86 | -49.30 | 5.04 | -- | -565.36 | -372.22 | -- | -- | 0.1636 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
Data as of Jul 23 2024. Currency figures normalised to Kintor Pharmaceutical Ltd's reporting currency: Hong Kong Dollar HKD
1.42%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 4.43m | 0.99% |
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.14m | 0.25% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 392.00k | 0.09% |
SSgA Funds Management, Inc.as of 03 Jul 2024 | 162.50k | 0.04% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 130.00k | 0.03% |
Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 58.50k | 0.01% |
Dimensional Fund Advisors LPas of 30 Apr 2024 | 28.50k | 0.01% |
The Vanguard Group, Inc.as of 31 Jan 2023 | 15.06k | 0.00% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 14.50k | 0.00% |
DFA Australia Ltd.as of 30 Apr 2024 | 310.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.